

BSW Formulary Update – Following APC September 2021 meeting

Lipid management update

- [National Guidance for Lipid Management for Primary and Secondary Prevention of CVD](#) and [Statin Intolerance Pathway](#) have been added to the BSWformulary entry for the recently added drug [Bempedoic Acid](#). These resources have been produced by NICE/ACC and we expect them to be updated imminently to incorporate another new NICE approved drug that will shortly be added to BSWformulary, [Inclisiran](#).
 Inclisiran and Bempedoic Acid will soon move to **GREEN TLS**. NHSE/I have set up a novel funding mechanism which supports prescribing of inclisiran in primary care and promotes a Population Health Management (PHM) approach to lipid management. The goal of the PHM approach is to implement a large-scale intervention, with patients proactively identified and their lipid management optimised in primary care. Support for primary care will be provided by ACC and the WEAHSN and a primary care LES is expected for the new financial year to have a focus on CVD prevention.
 Further updates to follow.

New and Updated Prescribing Guidelines/Shared Care Guideline

- **BSW Primary Care Antibiotic Guidance** updated to include information from [NG199](#) the antimicrobial strategy for managing *C.difficile* infection. This update includes changing [Fidaxomin tablets](#) to **GREEN TLS** so they can be initiated in primary care as per NG199 which recommend fidaxomin as:
 - 2nd-line for a first episode of mild-to-moderate *C. difficile* infection;
 - 1st-line for a further episode of *C. difficile* infection within 12 weeks of symptom resolution (relapse);
 - 2nd-line for a further episode of *C. difficile* infection more than 12 weeks after symptom resolution (recurrence).

Prescribers in the community may still wish to seek specialist advice from micro or infectious disease specialist before starting treatment if unfamiliar with diagnosing and treating *C.difficile* infection. Note that **fidaxomicin is expensive (£1350 per 20 tablet course) and may not be routinely stocked** so we recommend the prescriber contacts community pharmacy before issuing prescription to establish how quickly it can be supplied.

New additions to BSWformulary

- [Trurapi insulin aspart 100units/ml solution for injection PFP and cartridges](#). Trurapi is a biosimilar of the rapid-acting insulin analogue NovoRapid (insulin aspart) and is added to formulary as first line insulin aspart in **new** patients **GREEN TLS**.
- [Casirivimab and imdevimab 120mg/ml \(Ronapreve®\)](#) for patients hospitalised due to COVID-19 added with **RED TLS**.
- [Varicella Vaccine \(inactivated\) \(Shingrix®\)](#) added with **GREEN TLS** for use in line with PHE shingle vaccine programme.

Aligned on BSWformulary

- [Methoxyflurane 3ml inhalation vapour \(Pentrox®\)](#) aligned as **RED TLS** for all trusts.
- [Pilocarpine 5ml tablets](#) aligned as **GREEN TLS**
- [Antacid and oxetacaine oral suspension](#) aligned for treating oral mucositis and oesophageal lesions when recommended by cancer care specialist only; not for routine use as an antacid **RED TLS** (unlicensed)

Other BSWformulary website updates

- Information for HCPs on the rebranding of Bydureon (discontinued) to [Bydureon BCise](#)
- [BSW Inflammatory Bowel Disease Pathways](#)
- [BSW Moderate Rheumatoid Arthritis HCD Treatment Pathway for adults](#)

What the BSW CCG formulary team are currently working on

- Working to improve the understanding of the definition of the Traffic Light System and initiation of shared care prescribing to improve engagement and adherence to the BSWformulary across primary and secondary care.
- Reviewing the national SCA consultations by RMOC.
- Reviewing COPD guidance including updated to the primary guidance on rescue packs, COPD guidance and COPD inhaler guide.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading or for further information email bswccg.formulary@nhs.net